Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer

American Journal of Pathology

Volumn 176, Issue 4, 2010, Pages 1619-1628

  Tsai, Chin Shaw Stella ^a   Chen, Hung Chang ^b   Tung, Jai Nien ^a   Tsou, Shung Sheng ^a   Tsao, Tang Yi ^a   Liao, Ching Fong ^c   Chen, Ying Chun ^c   Yeh, Chi Yuan ^a   Yeh, Kun Tu ^b,d   Jiang, Ming Chung ^a  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 77950580250     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090467     Document Type: Article

References (53)

1. Andre N, Schmiegel W: Chemoradiotherapy for colorectal cancer. Gut 2005, 54:1194-1202
2. Lurje G, Zhang W, Lenz HJ: Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 2007, 6:683-690 (Pubitemid 350221365)
3. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22:1797-1806
4. Carlson MR: Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol Diagn Ther 2009, 13:11-14
5. Losi L, Ponti G, Gregorio CD, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, de Leon MP: Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006, 202:663-670 (Pubitemid 44241682)
6. Di Gregorio C, Benatti P, Losi L, Roncucci L, Rossi G, Ponti G, Marino M, Pedroni M, Scarselli A, Roncari B, de Leon MP: Incidence and survival of patients with Dukes'A (stage T1 and T2) colorectal carcinoma: a 15-year population-based study. Int J Colorectal Dis 2005, 20:147-154 (Pubitemid 40227521)
7. Booth RA: Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett 2007, 249:87-96 (Pubitemid 46437280)
8. Provenzale D, Gray RN: Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst Monogr 2004, 33:45-55
9. Gupta AK, Brenner DE, Turgeon DK: Early detection of colon cancer: new tests on the horizon. Mol Diagn Ther 2008, 12:77-85
10. Stein U, Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007, 176:61-80
11. Huerta S: Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev Mol Diagn 2008, 8:277-288
12. Hundt S, Haug U, Brenner H: Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007, 16:1935-1953 (Pubitemid 47621167)
13. Tejpar S: The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer. Best Pract Res Clin Gastroenterol 2007, 21:1071-1087
14. Thomson DM, Krupey J, Freedman SO, Gold P: The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA 1969, 64:161-167
15. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993, 270:943-947 (Pubitemid 23244732)
16. Fong S, García Vega G, León V: Carcinoembryonic antigen fraction in digestive cancer. Neoplasma 1985, 32:199-208 (Pubitemid 15078949)
17. Sugarbaker PH: Role of carcinoembryonic antigen assay in the management of cancer. Adv Immun Cancer Ther 1985, 1:167-193
18. Chu DZ, Erickson CA, Russell MP, Thompson C, Lang NP, Broadwater RJ, Westbrook KC: Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Arch Surg 1991, 126:314-316
19. Brinkmann U, Brinkmann E, Gallo M, Pastan I: Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci USA 1995, 92:10427-10431
20. Jiang MC, Luo SF, Li LT, Lin CC, Du SY, Lin CY, Hsu YW, Liao CF: Synergic CSE1L/CAS, TNFR-1, and p53 apoptotic pathways in combined interferon-gamma/ adriamycin-induced apoptosis of Hep G2 hepatoma cells. J Exp Clin Cancer Res 2007, 26:91-99
21. Liao CF, Luo SF, Shen TY, Lin CH, Chien JT, Du SY, Jiang MC: CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)- induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. BMB Rep 2008, 41:210-216
22. Liao CF, Luo SF, Tsai CS, Tsao TY, Chen SL, Jiang MC: CAS enhances chemotherapeutic drug-induced p53 accumulation and apoptosis: use of CAS for high-sensitivity anticancer drug screening. Toxicol Mech Method 2008, 18:771-776
23. Behrens P, Brinkmann U, Wellmann A: CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis 2003, 8:39-44 (Pubitemid 36133136)
24. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M: Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 2004, 164:1131-1139 (Pubitemid 38387779)
25. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P: Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001, 158:2031-2041
26. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA, Stetler-Stevenson WG: Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994, 145:1285-1290 (Pubitemid 24378482)
27. Liao CF, Luo SF, Li LT, Lin CY, Chen YC, Jiang MC: CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J Exp Clin Cancer Res 2008, 27:15
28. Tsao TY, Tsai CS, Tung JN, Chen SL, Yue CH, Liao CF, Wang CC, Jiang MC: Function of CSE1L/CAS in the secretion of HT-29 human colorectal cells and its expression in human colon. Mol Cell Biochem 2009, 327:163-170
29. Aust DE, Muders M, Köhler A, Schmidt M, Diebold J, Müller C, Löhrs U, Waldman FM, Baretton GB: Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis. Scand J Gastroenterol 2004, 39:766-772 (Pubitemid 39093252)
30. Knösel T, Schlüns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I: Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia 2004, 6:23-28 (Pubitemid 38391946)
31. Tung MC, Tsai CS, Tung JN, Tsao TY, Chen HC, Yeh KT, Liao CF, Jiang MC: Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:1570-1577
32. 2α. Biomed Pharmacother 2009, 63:522-527
33. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, Springer, 2002, pp 113-124
34. Kutay U, Bischoff FR, Kostka S, Kraft R, Gorlich D: Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell 1997, 90:1061-1071 (Pubitemid 27408520)
35. Pickett JA, Edwardson JM: Compound exocytosis: mechanisms and functional significance. Traffic 2006, 7:109-116
36. Pieper-Bigelow C, Strocchi A, Levitt MD: Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990, 19:793-810
37. Blecker D, Abraham S, Furth EE, Kochman ML: Melanoma in the gastrointestinal tract. Am J Gastroenterol 1999, 94:3427-3433
38. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M, Gao X, Xu Q: Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 2004, 164:2039-2054 (Pubitemid 38669352)
39. Seiden-Long IM, Brown KR, Shih W, Wigle DA, Radulovich N, Jurisica I, Tsao MS: Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene 2006, 25:91-102 (Pubitemid 43050007)
40. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D, Sargent D; National Cancer Institute Expert Panel: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001, 93:583-596
41. Consensus NIH Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450 (Pubitemid 20331943)
42. Moosmann N, Heinemann V: Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008, 8:319-329 (Pubitemid 351836281)
43. Kulig J, Popiela T, Richter P, Klek S: Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer. Acta Chir Belg 2007, 107:297-301
44. Omachi T, Kawai Y, Mizuno R, Nomiyama T, Miyagawa S, Ohhashi T, Nakayama J: Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance. Cancer Lett 2007, 246:167-172 (Pubitemid 44959388)
45. Céspedes MV, Espina C, García-Cabezas MA, Trias M, Boluda A, Gómez del Pulgar MT, Sancho FJ, Nistal M, Lacal JC, Mangues R: Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007, 170:1077-1085 (Pubitemid 47339374)
46. Lemmens VE, van Lijnschoten I, Janssen-Heijnen ML, Rutten HJ, Verheij CD, Coebergh JW: Pathology practice patterns affect lymph node evaluation and outcome of colon cancer: a population-based study. Ann Oncol 2006, 17:1803-1809 (Pubitemid 44884056)
47. Demols A, Van Laethem JL: Adjuvant chemotherapy for colorectal cancer. Curr Gastroenterol Rep 2002, 4:420-426
48. Horzic M, Kopljar M: Minimal number of lymph nodes that need to be examined for adequate staging of colorectal cancer-factors influencing lymph node harvest. Hepatogastroenterology 2005, 52:86-89 (Pubitemid 40282637)
49. Kim HJ, Yu MH, Kim H, Byun J, Lee C: Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 2008, 41:685-692
50. Duffy MJ: CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998, 35:364-370
51. Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000, 20:1085-1091 (Pubitemid 30240680)
52. Korotkova EA, Gershteǐn ES, Prorokov VV, Kushlinskiǐ NE: Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors. Vopr Onkol 2009, 55:171-176
53. Møller Sørensen N, Vejgaard Sørensen I, Ørnbjerg Würtz S, Schrohl AS, Dowell B, Davis G, Jarle Christensen I, Nielsen HJ, Brünner N: Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008, 43:774-786